#SFHS2609377ADecree of April 10, 2026 Amending the Decree of January 31, 2023 on Pharmacist Substitution in Hybrid Groups
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This French decree expands and clarifies medical situations in which pharmacists can substitute medications within the specified hybrid groups. It adds new situations where substitution is allowed, which can increase flexibility for pharmacists and potentially improve medication availability for patients. However, some specific substitution scenarios have been removed, indicating a change in guidelines or best practices.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Added new medical situations where pharmacists can substitute medications.
- Removed specific medical situations previously allowed for substitution.
- Updates provide more flexibility and clarity in pharmacist substitution practices.
Obligations
What this law requires
Pharmacists must update their substitution practices to include ATC classes A06AD, D03A, D04A, D06A, D07, D10A, G01A, M02A, R01A, and S02 for all medical situations within hybrid groups, effective from the decree date
Pharmacists must cease performing medication substitutions for ATC class S02A in all medical situations within hybrid groups, as this classification has been removed from permissible substitution scenarios
Hybrid group pharmacies must ensure their internal protocols and guidelines reflect the newly permitted ATC classes for medication substitution in compliance with this decree
Pharmacists must continue to respect exclusion conditions specified in the original January 31, 2023 decree when performing substitutions for the newly added ATC classes
The decree must be published in the Journal officiel de la République française